Ep. 375 - Novartis' ADC gambit & regulation as catalyst for U.K. biotech

Novartis’s $1.1 billion acquisition of Myricx signals a strategic pivot toward NMT payloads in antibody-drug conjugates, marking a significant advancement in oncology. Simultaneously, the U.K. life sciences sector faces a regulatory evolution as MHRA CEO Lawrence Tallon advocates for proportionate oversight to accelerate innovation. In the United States, Representative Diana DeGette’s primary defeat jeopardizes the long-standing bipartisan consensus model for FDA reform, complicating future legislative efforts. Research into Parkinson’s disease via new molecular atlases highlights the critical roles of lysosomal stress and inflammation, suggesting that future therapies must target specific disease stages and brain regions. Meanwhile, the House Select Committee on China continues to scrutinize clinical trial data integrity, raising concerns about informed consent standards and the reliance on Chinese trial data for U.S. drug approvals.